Skip to main content

Colorectal Cancer

A Single-Center Experience of Trifluridine and Tipiracil With or Without Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer
Samantha Musson, PharmD, BCOP; Matthew Arango, PharmD, BCOP; Daniel Kendzierski, PharmD, BCOP; Rachel M. Smith, MPH; John Hays, MD, PhD
Read More
Meeting Highlights
NCCN Guidelines Update: Initial Colorectal Screening Lowered to Age 45
Read More
Acute-Onset Congestive Heart Failure After 5-Fluorouracil Administration in a Patient with Colon Cancer
Vincent J. Cascone, PharmD, BCOP
Read More
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
Abstract #CT06
Read More
Pembrolizumab Shows Long-Term Benefits in Patients with Metastatic Colorectal Cancer and MSI-H or dMMR
Read More
Meeting Highlights
Encorafenib plus Cetuximab Improves Quality of Life versus Standard of Care in Colorectal Cancer Associated with BRAF Mutation
Read More
Clinical and Budget Impact of Increasing Colorectal Cancer Screening by Blood- and Stool-Based Testing
Joshua A. Roth, PhD, MHA; Theo deVos, PhD; Scott D. Ramsey, MD, PhD
Read More
Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer
Read More

Results 1 - 8 of 8